Proteome Sciences AI Stock Analysis
Want to see GB:PRM full AI Analyst Report?
Proteome Sciences (PRM) AI Stock Analysis
Proteome Sciences
(LSE:PRM)
The overall score is very low, driven primarily by the company's dire financial state, including negative equity and persistent losses. Technical trends are bearish, and the negative P/E ratio confirms a lack of underlying profitability. The company faces significant solvency risks, making it a highly speculative investment.
Proteome Sciences (PRM) vs. iShares MSCI United Kingdom ETF (EWC)
- Market Cap
- GBP 4.77M
- Dividend Yield
- ―
- Average Volume (3M)
- 188.53K
- Price to Earnings (P/E)
- -1.9
- Beta (1Y)
- 0.19
- Revenue Growth
- -16.72%
- EPS Growth
- 36.28%
- Country
- UK
- Employees
- 32
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Medical - Specialties
Proteome Sciences Business Overview & Revenue Model
Company Description
Proteome Sciences plc provides contract research services for the identification, validation, and application of protein biomarkers in the United States, the United Kingdom, European Union, and internationally. The company offers TMT LC-MS2, a standa...
Proteome Sciences Financial Statement Overview
Summary
Financial health is critically weak. Declining revenues, negative gross margins, negative shareholders' equity, and a debt-to-asset ratio of 1.9 indicate severe financial distress. The only positive is an improving cash flow trend, but it remains negative.
Income Statement
15Very NegativeBalance Sheet
5Very NegativeCash Flow
25Negative| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 3.77M | 3.76M | 4.89M | 5.03M | 7.78M | 5.12M |
| Gross Profit | -956.00K | -1.01M | -167.00K | 1.16M | 4.77M | 2.96M |
| EBITDA | -1.30M | -1.74M | -1.52M | -1.14M | 2.01M | 625.00K |
| Net Income | -2.32M | -3.06M | -3.41M | -2.44M | 1.32M | 72.00K |
Balance Sheet | ||||||
| Total Assets | 7.67M | 8.26M | 9.21M | 11.46M | 12.43M | 10.04M |
| Cash, Cash Equivalents and Short-Term Investments | 1.10M | 781.00K | 1.13M | 2.03M | 3.99M | 2.39M |
| Total Debt | 15.95M | 15.77M | 14.52M | 13.47M | 11.91M | 11.69M |
| Total Liabilities | 17.57M | 17.79M | 15.72M | 14.52M | 13.28M | 12.82M |
| Stockholders Equity | -9.90M | -9.53M | -6.52M | -3.07M | -843.00K | -2.77M |
Cash Flow | ||||||
| Free Cash Flow | 367.00K | -143.00K | -1.05M | -718.00K | 2.14B | 8.80B |
| Operating Cash Flow | 425.00K | -46.00K | -826.00K | -481.00K | 3.88B | 10.52B |
| Investing Cash Flow | -56.00K | -97.00K | -224.00K | -424.00K | -21.67B | 4.27B |
| Financing Cash Flow | 461.00K | -204.00K | 151.00K | -1.06M | -209.00K | -400.00K |
Proteome Sciences Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For GB:PRM, the sentiment is Negative. The current price of 1.36 is below the 20-day moving average (MA) of 1.40, below the 50-day MA of 1.41, and below the 200-day MA of 1.61, indicating a bearish trend. The MACD of -0.01 indicates Positive momentum. The RSI at 46.39 is Neutral, neither overbought nor oversold. The STOCH value of 36.19 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for GB:PRM.
Proteome Sciences Peers Comparison
Overall Rating
GB:GDR49Neutral
GB:CLBX48Neutral
GB:GENI40Underperform
GB:PRM39Underperform
GB:VRCI38Underperform
GB:OPTI32Underperform
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| 49Neutral | GBP 14.45M | -0.82 | -1044.57% | ― | 65.60% | 74.84% | |
| 48Neutral | GBP 6.82M | -0.49 | -104.73% | ― | -56.10% | 41.10% | |
| 40Underperform | GBP 4.52M | -0.45 | -481.34% | ― | -10.81% | 42.67% | |
| 39Underperform | GBP 4.77M | -1.86 | 23.85% | ― | -16.72% | 36.28% | |
| 38Underperform | GBP 13.66M | -0.53 | -127.57% | ― | 77.87% | 84.36% | |
| 32Underperform | GBP 4.70M | -1.10 | -77.85% | ― | 11.90% | -2864.29% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| GB:PRM | Proteome Sciences | 1.36 | -0.29 | -17.58% | |
| GB:CLBX | ANGLE plc | 0.60 | -1.20 | -66.67% | |
| GB:GDR | Genedrive plc | 0.90 | 0.11 | 13.92% | |
| GB:OPTI | OptiBiotix Health | 4.55 | -3.70 | -44.85% | |
| GB:VRCI | Verici Dx Plc | 0.20 | -0.57 | -73.55% | |
| GB:GENI | GENinCode UK Ltd. | 0.60 | -1.70 | -73.91% |
Proteome Sciences Corporate Events
Proteome Sciences Adds Former KPMG International CFO Helen Spice to Board
PositiveProteome Sciences plc has strengthened its board with the appointment of Helen Spice as an independent non-executive director, effective immediately. Spice, a former CFO of KPMG International and current non-executive director at Barts Health NHS Tru...
Proteome Sciences Builds Order Book as Targeted Proteomics Demand and TMT Sales Rise
PositiveProteome Sciences reported interim revenues of £1.87m for the first half of 2026, broadly flat year-on-year, with lower services income offset by stronger TMT reagent sales and royalties, and an improved gross profit thanks to reduced costs. Manageme...
Proteome Sciences Wins Major GCLP Chemoproteomics Contract for Global Clinical Trials
PositiveProteome Sciences has secured a significant new clinical chemoproteomics contract that will be conducted under Good Clinical Laboratory Practice at its Frankfurt laboratories. The engagement, linked to the same protein studied in two earlier projects...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Nov 04, 2026
